BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26859679)

  • 1. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
    Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
    Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
    Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
    Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
    Li L; Yang J; Wang J; Kopeček J
    ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
    Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
    Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
    Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
    MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
    Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
    Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
    Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
    J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma.
    Song L; Chen Y; Ding J; Wu H; Zhang W; Ma M; Zang F; Wang Z; Gu N; Zhang Y
    J Mater Chem B; 2020 Feb; 8(5):895-907. PubMed ID: 31909406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
    Feugier P
    Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
    Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
    Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
    Engelhard M
    Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.